Division of Hematology and Bone Marrow Transplantation, Azienda Ospedaliero - Universitaria di Udine, Italy.
Leuk Res. 2013 Nov;37(11):1457-60. doi: 10.1016/j.leukres.2013.07.037. Epub 2013 Aug 11.
To test the recently developed EUTOS score in predicting optimal response to imatinib and the long-term outcome, 265 patients with early chronic phase chronic myeloid leukaemia treated with standard dose imatinib were analysed. Achievement of optimal response endpoints were higher in low-risk patients, though the difference was not statistically significant: PCyR at 6th month 86% vs 67% (p=0.06), CCyR at 12th month 80% vs 63% (p=0.09), MMR at 18th month 61% vs 36% (p=0.11). However, EUTOS score was predictive for the long-term response. With a median follow-up of 61 months, 53% high-risk patients experienced imatinib failure, compared to 23% in the low-risk group (p=0.013). Among high-risk patients, 4/17 (23%) progressed to accelerated/blastic phase or died, compared to 11/248 (5%) low-risk patients, with 5-year progression-free survival rates of 84±10% and 96±1%, respectively (p=0.04). Our data confirm that EUTOS score envisions the long-term outcome of imatinib therapy.
为了测试最近开发的 EUTOS 评分在预测伊马替尼最佳反应和长期结果方面的作用，分析了 265 例接受标准剂量伊马替尼治疗的早期慢性期慢性髓性白血病患者。低危患者达到最佳反应终点的比例较高，但差异无统计学意义：第 6 个月时 PCyR 为 86%比 67%（p=0.06），第 12 个月时 CCyR 为 80%比 63%（p=0.09），第 18 个月时 MMR 为 61%比 36%（p=0.11）。然而，EUTOS 评分可预测长期反应。中位随访 61 个月时，53%的高危患者发生伊马替尼耐药，而低危组为 23%（p=0.013）。在高危患者中，17 例中有 4 例（23%）进展为加速/急变期或死亡，而 248 例低危患者中仅有 11 例（5%），高危患者的 5 年无进展生存率分别为 84±10%和 96±1%，差异有统计学意义（p=0.04）。我们的数据证实，EUTOS 评分可预测伊马替尼治疗的长期结果。
